Dulaglutide
Therapeutic Dulaglutide hormone from the original Trulicity® commercial drug.
Reference Standard as Aliquots
Product Batch | Therapeutic Expiry Date
| Brand & Origin
| Amount per Aliquot
| Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2023.07 |
Trulicity® DE |
0.9 mg |
Unit: aliquot(s) |
319,00 €
/aliquot
|
|||
2024.04 |
Trulicity® DE |
0.9 mg |
Unit: aliquot(s) |
319,00 €
/aliquot
|
|||
2023.12 |
Trulicity® DE |
0.9 mg |
Unit: aliquot(s) |
319,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Trulicity® / Dulaglutide Reference Product
| Drug name | Trulicity® |
| INN | Dulaglutide |
| API type | Glycoprotein |
| Pharmacotherapeutic group | Drugs used in diabetes, blood glucose lowering drugs, excl. insulins |
| ATC code | A10BJ05 |
| Target of antibody | |
| General function | Dulaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as a monotherapy or in conjunction with other medicinal products for the treatment of diabetes. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. The molecule consists of 2 identical disulfide-linked chains, each containing a modified human GLP-1 analogue sequence covalently linked to a modified human immunoglobulin G4 (IgG4) heavy chain fragment (Fc) by a small peptide linker. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Dulaglutide improves glycaemic control through the sustained effects of lowering fasting, pre-meal and postprandial glucose concentrations in patients with type 2 diabetes starting after the first dulaglutide administration and is sustained throughout the once weekly dosing interval. |
| Original license holder | Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands |
| Marketing authorisation numbers | EU/1/14/956/004 EU/1/14/956/005 EU/1/14/956/009 EU/1/14/956/010 |
| Marketing authorisation holder | Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands |
| Name of the manufacturer of the biological active substance | Eli Lilly Kinsale Limited Dunderrow Kinsale Co. Cork Ireland |
| Name and address of the manufacturer(s) responsible for batch release | Eli Lilly Italia S.p.A. Via Gramsci 731/733 50019, Sesto Fiorentino Firenze (FI) Italy Lilly France 2, rue du Colonel Lilly 67640 Fegersheim France |
| Max shelf life | 2 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Sodium citrate Citric acid Mannitol Polysorbate 80 Water for injections |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
